Results 131 to 140 of about 67,058 (255)

Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm

American Journal of Hematology, Volume 101, Issue 9, Page 2288-2296, September 2026.
ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt, Christopher S. Wichman, Alyssa Bouska, Moataz Ellithi, Michael Haddadin, Javeed Iqbal, James E. Talmadge, Lori J. Maness, Krishna Gundabolu   +8 more
wiley   +1 more source

Management of iron overload in adult myelodysplastic syndrome. [PDF]

Hematology Am Soc Hematol Educ Program
Leitch HA, Buckstein R.
europepmc   +1 more source

Clinical Impact of Maximum Plasma Concentration of Busulfan in Pediatric Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 702-712, September 2026.
Busulfan's narrow therapeutic index and high pharmacokinetic (PK) variability warrant investigation of its exposure–toxicity relationship. We retrospectively analyzed 334 pediatric and young adult patients who underwent allogeneic hematopoietic stem cell transplantation at Seoul National University Children's Hospital between 2009 and 2020 and received
Sungyeun Bae, Jung Yoon Choi, Kyung Taek Hong, Bo Kyung Kim, Hyun Jin Park, Kyung‐Sang Yu, Su‐jin Rhee, Hyoung Jin Kang   +7 more
wiley   +1 more source

A Hematologic Mimic: Sarcoidosis Presenting With Myelodysplastic Syndrome-Like Marrow Dysplasia, Massive Splenomegaly, and Pancytopenia. [PDF]

Cureus
Singh S, Sharma J, Sharma D, Prasad A, Srivastav S.   +4 more
europepmc   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Seven-Year Course of Hypoplastic Myelodysplastic Syndrome Unmasked by Secondary and Neurological Syphilis. [PDF]

Mediterr J Hematol Infect Dis
Turunç A, Dinçyürek HD, Güvenç B.
europepmc   +1 more source

Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Patients with high‐risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) continue to face a substantial risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), which remains a leading cause of treatment failure.
Cuicui Lyu, Tianle Xie, Yedi Pu, Xianshuang Luan, Xia Xiao, Mingfeng Zhao, Hairong Lyu   +6 more
wiley   +1 more source

Myelodysplastic Syndrome in a Patient With Cronkhite-Canada Syndrome. [PDF]

Clin Case Rep
Shim KG, Khadarian K, Samadder J, Zhou J, Yi CA.   +4 more
europepmc   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

Brain Pathology, Volume 36, Issue 5, September 2026.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, María J. Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Manuel Portero‐Otín, Gerard Piñol‐Ripoll, Mónica Povedano, Pol Andrés‐Benito   +19 more
wiley   +1 more source

Successful Treatment of Refractory Sweet's Syndrome With Adalimumab in a Myelodysplastic Syndrome Patient. [PDF]

EJHaem
Ma L, Shen Y, Chang J, Suo S, Wang L, Zhu W, Qiao J, Tong H.   +7 more
europepmc   +1 more source